Biocon Launches New Biosimilars Bosaya and Aukelso in the U.S.
Biocon launches biosimilars - Bosaya and Aukelso in U.S.
Business Standard
Image: Business Standard
Biocon has launched two new biosimilars, Bosaya and Aukelso, in the United States, targeting patients with serious bone conditions. Both products, approved by the U.S. Food and Drug Administration in September 2025, aim to provide affordable treatment options through specialty pharmacies and healthcare providers.
- 01Biocon's Bosaya and Aukelso are now available in the U.S.
- 02Both products are biosimilars to Prolia and Xgeva, respectively.
- 03They received FDA approval and interchangeable designation in September 2025.
- 04The launch aims to enhance access to affordable treatment for bone conditions.
- 05Biocon continues to expand its leadership in oncology and immunology.
Advertisement
In-Article Ad
Biocon has officially launched Bosaya (denosumab-kyqq) and Aukelso (denosumab kyqq) in the United States, marking a significant expansion in its biosimilars portfolio. These products are biosimilars to Amgen's Prolia and Xgeva, respectively, and are now available by prescription nationwide through specialty pharmacies and healthcare providers. They were approved by the U.S. Food and Drug Administration (FDA) in September 2025, receiving an interchangeable designation that allows for substitution at the pharmacy level according to state laws. Shreehas Tambe, CEO & Managing Director of Biocon, emphasized that the introduction of these therapies broadens access to high-quality, affordable treatment options for patients with serious bone conditions. This launch reinforces Biocon's commitment to developing scalable access platforms for life-changing medicines in the U.S. and globally.
Advertisement
In-Article Ad
The launch of Bosaya and Aukelso will increase access to affordable treatment options for patients with serious bone conditions in the U.S., potentially lowering healthcare costs for these patients.
Advertisement
In-Article Ad
Reader Poll
Do you believe biosimilars will improve access to medications in the U.S.?
Connecting to poll...
More about Biocon
Read the original article
Visit the source for the complete story.